Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, the company’s unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in their laboratories.

Regeneron is committed to helping patients with eye diseases, including continuing to advance the treatment of vision-threatening conditions.